Screener / SEC EDGAR /CIK 0001822479 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

Sotera Health Co SHC

Compare with peers Embed
The 10-K against last year's

179 changes: 13 added, 27 removed, 134 reworded, 5 quiet changes

10-K Feb 24, 2026 vs Feb 27, 2025

10-K 0001822479-26-000015 (Feb 24, 2026) vs 10-K 0001822479-25-000015 (Feb 27, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

245 paragraphs · 5 new · 109 reworded · 9 gone · 10-K Feb 24, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 120 · 50% changed Every version of it
Government these permits and licenses could delay or private civil antitrust actions prevent us from fulfilling our obligations to our customers or suppliers, which could harm our business, prospects, financial condition or results of operations.
Paragraph 189 · 48% changed Every version of it
Our ability to make timely payments of principal and interest on our debt obligations, including our obligations under the Combined Senior Secured Credit Facilities, depends on our ability to generate positive cash flows from operations, which is subject to general economic conditions, competitive pressures and certain financial, business and other factors beyond our control. If our cash flows and capital resources are insufficient to make these payments, we may be required to seek additional financing sources, reduce or delay capital expenditures, sell assets or operations or refinance our indebtedness. These actions could have a material adverse effect on our business, financial conditions and results of operations. In addition, we may not be able to take any of these actions, and even if successful, these actions may not permit us to meet our scheduled debt service obligations. Our ability to restructure or refinance our existing indebtedness will depend on, among other things, the condition of the capital markets and our financial condition at the time. We may not be able to restructure or refinance any of our indebtedness on commercially reasonable terms or at all. If we cannot make scheduled payments on our debt, we will be in default and the outstanding principal and interest on our debt could be declared to be due and payable, in which case we could be forced into bankruptcy or liquidation or required to substantially restructure or alter our business operations or debt obligations.
Paragraph 98 · 48% changed Every version of it
The potential worsening of macro-economic conditions, including changes in tariff and trade policies, slower growth or recession, recessionary conditions, the inflationary environment, tighter credit, higher high interest rates and currency fluctuations, may cause customers to modify, delay or cancel plans to purchase our products and services and suppliers may significantly and rapidly increase their prices or reduce their output because of cash flow problems. Any inability of current or potential customers to purchase or pay for our products because of such declining economic conditions or changes in spending patterns at medical device, pharmaceutical and biotechnology companies may have a negative impact on our business, prospects, financial condition or results of operations. Overall demand for our products could be reduced as a result of a global economic recession or political unrest, especially in such areas as the medical device, pharmaceutical, food safety and other end markets that we serve.
Paragraph 83 · 46% changed Every version of it
If Co-60 source suppliers in other countries, including China, India, Argentina or Russia, significantly increase their involvement in the global Co-60 sources market, this could have a material adverse effect over the long-term on our business, prospects, financial condition or results of operations. Several customers of our Nordion business are themselves providers of sterilization services and therefore are competitors of our Sterigenics business. If these customers were to shift to a different supplier of Co-60 because they prefer to use a supplier not affiliated with us or for any other reason, this could materially adversely affect our business, prospects, financial condition or results of operations. Further, if a Nordion customer were to lose market share to a competitor using an alternative sterilization provider, we would similarly lose sales volumes, which may have a material adverse effect on our business, prospects, financial condition or results of operations.
Paragraph 55 · 46% changed Every version of it
We face the risk of financial exposure to product and other liability claims alleging that our failure to adequately perform our services resulted in adverse effects, including product recalls or seizures, adverse publicity and safety alerts. In our Sterigenics business, for example, while our customers are generally responsible for determining the cycle parameters (the levels of temperature, humidity and EO concentration to which products are exposed during the sterilization process and the duration of such exposure) or dosage specifications (the amount of gamma or E-beam irradiation to which products are exposed) for their products, we are required to certify that such cycle or dosage parameters were achieved. If we fail to process a customer’s product in accordance with the cycle parameters, dosage specifications or testing requirements prescribed by the customer, our standard contract requires us to inform our customer of the nonconformance, to reprocess or retest the product if that is a feasible alternative and to reimburse the customer (subject to a maximum) for the cost of any products that are damaged as a result of the nonconformance. We could be held liable for personal injury, contractual or other damages that are alleged to result from improper or incorrect processing, cycle parameters or dosage specifications, testing or product damage. Even where processing occurred within cycle parameters, we have faced and may face future claims resulting from processing. In our Nelson Labs business, if we fail to perform our services in accordance with regulatory requirements for medical products, regulatory authorities may take action against us or our customers. Regulatory authorities may disqualify certain analyses from consideration in connection with marketing authorizations, which could result in our customers not being able to rely on our services in connection with their submissions, may subject our customers to additional studies or testing and delays in the development or authorization process, and may lead our customers to take actions such as terminating their contracts with us. We could also face claims that we performed erroneous or out-of-specification testing or data integrity complaints, any of which could require retesting and result in claims of economic or other loss or personal injury.
Paragraph 227 · 44% changed Every version of it
Our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws, the Stockholders Agreement and Delaware law contain provisions that might discourage, delay or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions include:
Paragraph 62 · 42% changed Every version of it
In March 2024, the US U.S. EPA announced final rules under NESHAP the National Emissions Standards for Hazardous Air Pollutants (“NESHAP”) to govern EO sterilization facilities in the United States. States, and on April 5, 2024, the final NESHAP regulation became effective. The final regulation requires EO sterilization facilities to implement additional air pollution technologies, practices and procedures designed to further reduce EO emissions. For facilities like ours, the final NESHAP regulation imposes new requirements such as higher efficiencies for EO emission controls, implementation of permanent total enclosure capture technology, and use of CEMS. Our operations are required to comply with the final NESHAP EO sterilizer regulation by April 6, 2026 and to conduct a compliance test and demonstrate compliance within 180 days after that date.
Paragraph 34 · 40% changed Every version of it
Any incident at or emission from any of our EO, gamma or lab facilities that causes harm to workers or people who live, work, attend school or otherwise spend significant amounts of time near our facilities, or the interruption of normal operations at our facilities, could result in claims against us and, if those claims are successful, substantial liability to us. We are currently the subject of lawsuits alleging that purported EO emissions from certain of our current and former facilities have resulted in toxicological or health-related impacts on the environment and the communities that surround these facilities. We deny these allegations. We have also from time to time been involved with workers’ compensation claims relating to potentially hazardous materials. We may be subject to similar claims in the future, and one or more adverse judgments could result in significant liability for us and have a material adverse effect on our business, financial condition and results of operations. See related Risk Factors “—We are currently defending certain litigation, and we are likely to be subject to additional litigation in the future” and “—Potential health risks associated with the use of EO may subject us to future liability claims and associated adverse effects.”

MD&A

148 paragraphs · 8 new · 82 reworded · 18 gone · 10-K Feb 24, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 58 · 49% changed
We use Adjusted Net Income and Adjusted EBITDA, non-GAAP financial measures, as the principal measures of our operating performance. Management believes Adjusted Net Income and Adjusted EBITDA are useful because they allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. In addition, we believe Adjusted Net Income and Adjusted EBITDA will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses Adjusted Net Income and Adjusted EBITDA in their financial analysis and operational decision-making, and Adjusted EBITDA serves as the basis for the metric we utilize to determine attainment of our primary annual incentive program. Adjusted Net Income and Adjusted EBITDA may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.
Paragraph 13 · 49% changed
For more information regarding our reportable segments please refer to See Item 1. “Business” 3, “Legal Proceedings” and Note 21, “Segment 19, “Commitments and Geographic Information” Contingencies,” to our consolidated financial statements.
Paragraph 48 · 48% changed
(f)Represents Amounts presented represent (i) the cost to settle 79 97 pending and threatened EO claims in Georgia under a settlement Illinois pursuant to the term sheet entered into on December 21, 2023. See Note 19, “Commitments April 3, 2025 and Contingencies.” (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.
Paragraph 113 · 47% changed
(thousands of U.S. dollars) 2024 2023 Net Cash Provided by (Used in): Operating activities $ 224,164 $ (147,732) Investing activities (178,996) (214,906) Financing activities (50,564) 265,959 Effect of foreign currency exchange rate changes on cash and cash equivalents 16,074 (17,393) 2,039 Net (decrease) increase in cash and cash equivalents, including restricted cash, during the period $ (22,789) $ (94,640)
Paragraph 107 · 47% changed
On May 30, 2024, SHH, the Company, certain subsidiaries of the Company (the “Guarantors”), Company, and Wilmington Trust, National Association, as trustee, paying agent, registrar, transfer agent and notes collateral agent, entered into an Indenture (the “Indenture”) governing SHH’s $750.0 million aggregate principal amount of 7.375% senior secured notes due 2031 (the “Secured Notes”) issued in May 2024. The Secured Notes will pay interest semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2024, at a rate of 7.375% per year, and will mature on June 1, 2031. The Secured Notes may be redeemed, at any time or from time to time, in whole or in part, on or after June 1, 2027 at the redemption prices specified in the Indenture, together with accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. At any time or from time to time, prior to June 1, 2027, the Secured Notes may be redeemed, in whole or in part, at a redemption price equal to 100% of the aggregate principal amount thereof plus a make-whole premium, together with accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. In addition, at any time or from time to time, prior to June 1, 2027, SHH may redeem up to 40% of the aggregate principal amount of the Secured Notes (including any additional Secured Notes issued under the Indenture) with an amount not to exceed the net cash proceeds from certain equity offerings at a redemption price equal to 107.375% of the aggregate principal amount thereof plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. Further, at any time or from time to time, on or before June 1, 2027, SHH may redeem up to 10% of the then outstanding aggregate principal amount of Secured Notes (including any additional Secured Notes issued under the Indenture) during each of the twelve-month periods ending after the issue date, at a redemption price equal to 103% of the aggregate principal amount thereof, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date.
Paragraph 76 · 46% changed
For the years ended December 31, 2024, 2023 (e)Represents litigation and 2022, we recorded costs of $32.7 million, $45.3 million and $72.6 million, respectively, representing other professional fees and other expenses related to litigation associated with our EO sterilization facilities.
Paragraph 104 · 45% changed
On May 30, 2024, September 17, 2025, the Company and SHH entered into Amendment No. 4 6 (“Amendment No. 4”) 6”) to the Senior Secured Credit Facilities. Agreement. Among other changes, Amendment No. 4 6 provides for Refinancing the refinancing lenders to provide term loans (the “Repriced Term Loans Loans”) to SHH in an aggregate principal amount of $1,509.4 million. Pursuant $1,419.5 million, which reflects the balance after the Company’s application of $75.0 million of available cash to repay outstanding borrowings under its term loan facility. Amendment No. 4, 6 also reduced the Refinancing interest rate spread by 0.50% across term loans under the facility, such that the Repriced Term Loans shall have an applicable interest rate margin per annum equal to (i) ABR plus 2.25% for ABR Loans (as defined in the Credit Agreement), (ii) daily simple Secured Overnight Financing Rate (“SOFR”) plus 3.25% for RFR Loans Adjusted Term SOFR (as defined in the Credit Agreement) and (iii) Term plus 2.50%, with a 0.00% floor (with optionality for the Company to elect Alternate Base Rate (“ABR”) plus 1.50% or Adjusted Daily Simple SOFR plus 3.25% for Term Benchmark Loans (as 2.50% (each as defined in the Credit Agreement), Agreement)). This pricing reflects both the 0.50% reduction implemented through Amendment No. 6 and a 0.25% contractual pricing step-down that was triggered in each case with a 0% applicable floor and the applicable interest rate margin shall be August 2025. The Repriced Term Loans are also subject to a pricing step-down “soft call” premium of 0.25% when 1.00% for certain repricing transactions with respect to the Senior Secured Leverage Ratio (as defined in Repriced Term Loans that occur within the Credit Agreement) is less than or equal to 3.30:1.00. six-month period after the effective date of Amendment No. 6. The Refinancing Repriced Term Loans amortize at a rate of 1.00% per annum and mature on May 30, 2031. The weighted average interest rate on borrowings under the Refinancing Term Loans for the year ended December 31, 2024 was 8.29%.
Paragraph 46 · 44% changed
Interest expense, net increased $21.8 decreased $9.0 million, or 15.3%, 5.4%, for the year ended December 31, 2024 2025 as compared to the prior year. Lower The decrease was due to a lower weighted average interest rate on our outstanding borrowings, partially offset by a lower favorability from interest rate derivative activity of $15.0 million coupled with an $8.4 million decline activity, which resulted in interest income on cash and cash equivalents on deposit at financial institutions were the primary drivers of the increase a net reduction in interest expense, net. net of $8.4 million. The weighted average interest rate on our outstanding borrowings for the year ended December 31, 2025 was 7.29% compared to 8.16% for the year ended December 31, 2024.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors262 words changed in this paragraph; it is 42% similar to last year's version.
We face the risk of financial exposure to product and other liability claims alleging that our failure to adequately perform our services resulted in adverse effects, including product recalls or seizures, adverse publicity and safety alerts. In our Sterigenics business, for example, while our customers are generally responsible for determining the cycle parameters (the levels of temperature, humidity and EO concentration to which products are exposed during the sterilization process and the duration of such exposure) or dosage specifications (the amount of gamma or E-beam irradiation to which products are exposed) for their products, we are required to certify that such cycle or dosage parameters were achieved. If we fail to process a customer’s product in accordance with the cycle parameters, dosage specifications or testing requirements prescribed by the customer, our standard contract requires us to inform our customer of the nonconformance, to reprocess or retest the product if that is a feasible alternative and to reimburse the customer (subject to a maximum) for the cost of any products that are damaged as a result of the nonconformance. We could be held liable for personal injury, contractual or other damages that are alleged to result from improper or incorrect processing, cycle parameters or dosage specifications, testing or product damage. Even where processing occurred within cycle parameters, we have faced and may face future claims resulting from processing. In our Nelson Labs business, if we fail to perform our services in accordance with regulatory requirements for medical products, regulatory authorities may take action against us or our customers. Regulatory authorities may disqualify certain analyses from consideration in connection with marketing authorizations, which could result in our customers not being able to rely on our services in connection with their submissions, may subject our customers to additional studies or testing and delays in the development or authorization process, and may lead our customers to take actions such as terminating their contracts with us. We could also face claims that we performed erroneous or out-of-specification testing or data integrity complaints, any of which could require retesting and result in claims of economic or other loss or personal injury.

Source: Item 1A, 10-K 0001822479-26-000015 vs Item 1A, 10-K 0001822479-25-000015

MD&A231 words changed in this paragraph; it is 45% similar to last year's version.
On May 30, 2024, September 17, 2025, the Company and SHH entered into Amendment No. 4 6 (“Amendment No. 4”) 6”) to the Senior Secured Credit Facilities. Agreement. Among other changes, Amendment No. 4 6 provides for Refinancing the refinancing lenders to provide term loans (the “Repriced Term Loans Loans”) to SHH in an aggregate principal amount of $1,509.4 million. Pursuant $1,419.5 million, which reflects the balance after the Company’s application of $75.0 million of available cash to repay outstanding borrowings under its term loan facility. Amendment No. 4, 6 also reduced the Refinancing interest rate spread by 0.50% across term loans under the facility, such that the Repriced Term Loans shall have an applicable interest rate margin per annum equal to (i) ABR plus 2.25% for ABR Loans (as defined in the Credit Agreement), (ii) daily simple Secured Overnight Financing Rate (“SOFR”) plus 3.25% for RFR Loans Adjusted Term SOFR (as defined in the Credit Agreement) and (iii) Term plus 2.50%, with a 0.00% floor (with optionality for the Company to elect Alternate Base Rate (“ABR”) plus 1.50% or Adjusted Daily Simple SOFR plus 3.25% for Term Benchmark Loans (as 2.50% (each as defined in the Credit Agreement), Agreement)). This pricing reflects both the 0.50% reduction implemented through Amendment No. 6 and a 0.25% contractual pricing step-down that was triggered in each case with a 0% applicable floor and the applicable interest rate margin shall be August 2025. The Repriced Term Loans are also subject to a pricing step-down “soft call” premium of 0.25% when 1.00% for certain repricing transactions with respect to the Senior Secured Leverage Ratio (as defined in Repriced Term Loans that occur within the Credit Agreement) is less than or equal to 3.30:1.00. six-month period after the effective date of Amendment No. 6. The Refinancing Repriced Term Loans amortize at a rate of 1.00% per annum and mature on May 30, 2031. The weighted average interest rate on borrowings under the Refinancing Term Loans for the year ended December 31, 2024 was 8.29%.

Source: Item 7, 10-K 0001822479-26-000015 vs Item 7, 10-K 0001822479-25-000015

Accounting Policies179 words changed in this paragraph; it is 30% similar to last year's version.
We performed a quantitative assessment of all reporting units (Sterigenics, Nordion and Nelson Labs) as of October 1, 2024. 2025. The fair value of each reporting unit was calculated using a discounted cash flow analysis which was dependent on subjective market participant assumptions determined by management. We further corroborated these discounted cash flow analyses utilizing a market approach to determine the estimated enterprise fair value. Assumptions used in the analyses included discount rates, revenue growth rates and projected operating cash flows. Estimates of future cash flows are based upon relevant data at a point-in-time, are subject to change, and could vary from actual results. The estimated fair value of each reporting unit exceeded its carrying amount by a sufficient margin to support a positive assertion that goodwill is not impaired. We performed a qualitative impairment assessment to evaluate any potential impairment to the indefinite-lived intangible assets. We considered significant events and circumstances that could affect the significant inputs used to determine the estimated fair value of the indefinite-lived intangible assets, and determined, after considering the totality of evidence that it is not more likely than not that the indefinite-lived intangible assets are impaired. There have been no other significant events or circumstances that occurred since the annual assessment date of October 1 that would change the conclusions reached above.

Source: Item 8, Note 1 – Significant Accounting Policies, 10-K 0001822479-26-000015 vs Item 8, Note 1 – Significant Accounting Policies, 10-K 0001822479-25-000015

Legal Proceedings3 words changed in this paragraph; it is 98% similar to last year's version.
In addition to the matters identified in Note 19, “Commitments and Contingencies,” to our consolidated financial statements for the year ended December 31, 2024 2025 contained in this Annual Report on Form 10-K, and incorporated into this item Item 3 by reference, we report matters, if any, that constitute material pending legal proceedings, other than ordinary course litigation incidental to our business, to which we are or any of our subsidiaries is a party. SEC regulations require disclosure of environmental proceedings that involve a government authority and potential monetary sanctions that the Company reasonably believes will

Source: Item 3, 10-K 0001822479-26-000015 vs Item 3, 10-K 0001822479-25-000015

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of SHC's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 27, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
imposes new requirements such as higher efficiencies for EO emission controls, implementation of permanent total enclosure capture technology, and use of CEMS. The revised final NESHAP regulation generally allows two years for compliance. On March 12, 2025, the U.S. EPA announced that it was reconsidering the NESHAP regulation applicable to commercial sterilizers. On July 17, 2025, the White House issued a CAA proclamation providing a two-year exemption for certain sterilization facilities to allow time to obtain and install new control technology and implement required changes. Although our operations are covered by this exemption, we continue progressing certain changes to our facilities to comply with the final NESHAP EO sterilizer regulation. Additionally, a complaint was filed in January 2026 in the U.S. District Court for the District of Columbia against the President, U.S. EPA and the U.S. EPA Administrator seeking injunctive relief that would, if granted, invalidate the exemption and therefore require our facilities to comply with the original timeframe.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Despite the Company’s security measures, cybersecurity threats, cybersecurity incidents, outages, malfunctions, or disruptions involving our systems or those of our third party business partners, or any failure by us or our third-party business partners to
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
The introduction of AI and machine-learning technologies, into internal processes, third-party services and/or new and existing offerings may result in new or expanded risks and liabilities, including due to enhanced governmental or regulatory scrutiny, litigation, compliance issues, ethical concerns, confidentiality or security risks, as well as other factors that could adversely affect our business, reputation and financial results. In addition, our personnel could, unbeknownst to us, improperly utilize AI and machine learning-technology while carrying out their responsibilities. The use of AI in third-party services and the development of our products and services could also cause loss of intellectual property, as well as subject us to risks related to intellectual property infringement or misappropriation, data privacy and cybersecurity. The use of AI can lead to unintended consequences, including generating content that appears correct but is factually inaccurate, misleading or otherwise flawed, or that results in unintended biases and discriminatory outcomes, which could harm our reputation and business and expose us to risks related to inaccuracies or errors in the output of such technologies. The Company has established a cross-functional AI committee intended to support the identification and mitigation of risks associated with incorporating AI technologies into our processes.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
As of December 31, 2025, our total indebtedness was approximately $2,169.5 million, all of which is indebtedness of our subsidiary Sotera Health Holdings, LLC (“SHH”) that is guaranteed by the Company and certain of our other subsidiaries.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
As of December 31, 2024, our total indebtedness was approximately $2,255.6 million, all of which is indebtedness of Sotera Health Holdings, LLC (“SHH”) that is guaranteed by the Company and certain of our other subsidiaries. We also had an additional $409.8 million of unutilized capacity under our Revolving Credit Facility (as defined herein) at that date (without giving effect to $14.0 million of letters of credit that were outstanding). On May 30, 2024, the Company and SHH entered into Amendment No. 4 (“Amendment No. 4”) to the Senior Secured Credit Facilities. Among other changes, Amendment No. 4 provides for term loans (the “Refinancing Term Loans”) to SHH in an aggregate principal amount of $1,509.4 million. On May 30, 2024, SHH, the Company and certain subsidiaries of the Company (the “Guarantors”), and Wilmington Trust, National Association, as trustee, paying agent, registrar, transfer agent and notes collateral agent, entered into an indenture (the “Indenture”) governing SHH’s $750.0 million aggregate principal amount of 7.375% Senior Secured Notes due 2031 (the “Secured Notes”) issued in 2024. The Secured Notes pay interest semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2024, at a rate of 7.375% per year, and will mature on June 1, 2031. Please refer to Note 9, “Long-Term Debt” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” for further information.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
$1,505.6 million of our $2,255.6 million outstanding principal amount of indebtedness is variable interest rate debt. Our estimated debt service obligations for the next 12 months, which are comprised of principal and interest payments, are $183.7 million, a portion of which are based on Term SOFR benchmark interest rate as of December 31, 2024. For the year ended
Read it in 10-K Feb 27, 2025 at sec.gov
Show the other 55
RemovedRisk Factors
December 31, 2024, our cash flow used for debt service totaled $184.9 million, which was comprised of $5.0 million of principal payments on the Term Loan (as defined herein) and interest payments of $179.9 million on all of our outstanding debt.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Term SOFR and certain other interest “benchmarks” are subject to regulatory guidance and reform that we expect will cause interest rates under our current or future debt agreements to perform differently than in the past or could cause other unanticipated consequences.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Because our Senior Secured Credit Facilities bear interest at variable interest rates, based on the Term SOFR and certain other interest “benchmarks,” fluctuations in interest rates could have a material effect on our business. We currently utilize, and may in the future utilize, derivative financial instruments such as interest rate swaps or interest rate caps to hedge some of our exposure to interest rate fluctuations, but such instruments may not be effective in reducing our exposure to interest fluctuations, and we may discontinue utilizing them at any time. As a result, we may incur higher interest costs if interest rates increase. These higher interest costs could have a material adverse impact on our financial condition and the levels of cash we maintain for working capital.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
As of February 20, 2025, the Sponsors own approximately 43.4% of our outstanding common stock and retain the right to designate over a majority of our directors. The Stockholders Agreement contains agreements with respect to certain other matters, including the election of directors; mergers, consolidations and acquisitions; the sale of all or substantially all of our
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
•providing that for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR have the right (individually) to designate at least three directors for election to our board of directors, certain board approvals, including amendments to our Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws and certain specified corporate transactions, including certain acquisitions, mergers, other business combination transactions and dispositions, may be effected only with the affirmative vote of 75% of our board of directors, in addition to any other vote required by applicable law;
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedRisk Factors
Any disruption in the availability of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of current geopolitical instability against Russia by the United States, Canada, the United Kingdom, and and/or the European Union, or sanctions by Russia against those countries, may have a material adverse effect on our operating results.” and “—We conduct sales and distribution operations on a worldwide basis and are subject to a variety of risks associated with doing business outside the United States.”
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The conflict between Israel and Hamas and Hamas’ allies, including Iran and factions in Lebanon, and its potential ramifications for the Middle East Geopolitical conflicts have caused and and, in the future, may continue to cause instability and volatility in global markets and adversely impact global supply chains, including potentially disrupting shipping channels.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Although we and other organizations disagree with the US EPA’s assessments of the carcinogenic potency of EO, Sterigenics’ facilities and other EO facilities could continue to be the subject of unfavorable air quality assessments, regulations and other initiatives as risk assessments of EO continue to evolve.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In March 2024, the US EPA announced final rules under NESHAP the National Emissions Standards for Hazardous Air Pollutants (“NESHAP”) to govern EO sterilization facilities in the United States. States, and on April 5, 2024, the final NESHAP regulation became effective.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In addition, in the past, following periods of volatility in the overall market and the market price of companies’ securities, securities class action litigation has often been instituted against these companies, and we have been named as a defendant in such a putative securities class action of this kind that was dismissed at the trial court level and is currently pending against us. on appeal.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Material increases in the price of labor, raw materials, or energy could have a material adverse effect on our business, prospects, financial condition or results of operations, particularly if we are unable to increase the prices to our customers of our products or services to offset inflationary cost trends or if we are unable to achieve cost savings to offset such cost increases, our profits and operating results could be adversely affected. trends.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In 2016, the US EPA published its Integrated Risk Information System toxicity assessment of EO (the “2016 IRIS Assessment”), and, since 2018, the US EPA has published National Air Toxics Assessments, which have been succeeded by Air Toxics Screening Assessments.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For example, although EO is present in the environment from a variety of sources and naturally produced by the human body, the US EPA has identified a potential for increased risk of certain cancers from exposure to EO emitted from sterilization facilities.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Grand Prairie, Texas; and Vernon, California and may be filed in the future relating to these or Sterigenics’ other EO facilities; these These threats of additional EO lawsuits are comparable to threats that have similarly been made against other companies within our industry.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Grand Prairie, Texas; and Vernon, California Additional EO lawsuits have been threatened and may be filed in the future relating to these or Sterigenics’ other our EO facilities; facilities in the United States; these threats of additional EO lawsuits are comparable to threats that have similarly been made against other companies within our industry.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The potential worsening of macro-economic conditions, including changes in tariff and trade policies, slower growth or recession, recessionary conditions, the inflationary environment, tighter credit, higher high interest rates and currency fluctuations, may cause customers to modify, delay or cancel plans to purchase our products and services and suppliers may significantly and rapidly increase their prices or reduce their output because of cash flow problems.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In 2016, the US EPA published its Integrated Risk Information System toxicity assessment of EO (the “2016 IRIS Assessment”), and, since 2018, the US EPA has published National Air Toxics Assessments, which have been succeeded by Air Toxics Screening Assessments. U.S.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
Our business is highly competitive, and if we fail to compete successfully, our business, prospects, financial condition or results of operations may be materially adversely affected.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
Most of our customer contracts for sterilization services allow us to pass through our all direct material costs, but we may not be able to immediately or completely implement increases in the prices of our products and services.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
We may incur impairment charges on our goodwill and other intangible assets with indefinite lives as well as other long-lived assets and intangible assets with definite lives, which could negatively impact adversely affect our business, financial condition or results of operations.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
On September 17, 2025, the Company and SHH entered into Amendment No. 6 to the Credit Agreement. Amendment No. 6 reduced the interest rate to Adjusted Term SOFR (as defined in the Credit Agreement) plus 2.50%, with a 0.00% floor.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
•Litigation costs. On April 3, 2025 and July 23, 2025, Sterigenics entered into binding term sheets to resolve 97 and 129 EO claims, respectively, against Sterigenics relating to its former facility in Willowbrook, Illinois. Pursuant to the term sheets, Sterigenics agreed to pay $30.9 million and $34.0 million, respectively, allowing for the settling plaintiffs’ claims to be dismissed with prejudice.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Amortization of intangible assets primarily consists of expense associated with customer relationship, proprietary technology, trade names and other intangible assets. Amortization expense fluctuates when we have an acquisition, disposition, impairment charge, or as asset useful lives expire.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
(d)Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with secondary offerings and shareholder engagement.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Under the debt agreements summarized below, at December 31, 2025 we and SHH, our wholly owned subsidiary, had debt payment obligations under (a) a term loan in the amount of $1,419.5 million, (b) a revolving credit facility, which supported operationally-related letters of credit but was otherwise undrawn, and which provides to us capacity up to $600.0 million for future potential borrowings, and (c) $750.0 million of senior secured notes. Our debt agreements also include additional covenants, conditions and rights to request additional debt, as summarized below.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
The Company and SHH had previously entered into Amendment No. 4 to the Credit Agreement on May 30, 2024, respectively. See Note 9, “Long-Term Debt” to the Financial Statements for a description of this amendment.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
The Senior Secured Credit Facilities and the Indenture contain certain covenants and events of default. Additionally, all of SHH’s obligations under the Senior Secured Credit Facilities and the Indenture are unconditionally guaranteed by the Company and certain domestic restricted subsidiaries. For additional information about our Senior Secured Credit Facilities, the Indenture and the Secured Notes, including the covenants and events of default, refer to Note 8, “Long-Term Debt,” to our Financial Statements.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
We are a trusted partner to approximately 5,000 customers in over 50 countries. We strive to give our customers confidence that their products meet regulatory, safety and effectiveness requirements. With our industry-recognized scientific and technological expertise, we help to promote the safety of millions of patients and healthcare practitioners around the world every year. Across our 62 facilities worldwide, we have over 3,000 employees who are dedicated to safety and quality.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
As discussed in Item 1A, “Risk Factors”, a portion of our supply of Co-60 is generated by Russian nuclear reactors. We continue to monitor the potential for disruption in the supply of Co-60 from Russian nuclear reactors. There was no impact to our supply or revenue in the year ended December 31, 2024.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
•Litigation costs. We are currently the subject of tort lawsuits alleging injury by purported exposure to EO used, emitted or released by current facilities in Atlanta, Georgia and Vernon, California and our former facility in Willowbrook, Illinois. Additional EO lawsuits have been threatened relating to Sterigenics’ former facility in Willowbrook and existing facilities in Atlanta, Georgia; Charlotte, North Carolina; Grand Prairie, Texas; and Vernon, California and may be filed in the future relating to these or Sterigenics’ other EO facilities; these threats of additional EO lawsuits are comparable to threats that have similarly been made against other companies within our industry. In addition, we are defendants in a lawsuit brought by the State of New Mexico Attorney General alleging that emissions of EO from our Santa Teresa facility negatively impacted Santa Teresa and surrounding communities. We maintain that these facilities did not pose and do not pose any safety risk to their surrounding communities. We deny the allegations in these lawsuits and are vigorously defending against these claims. See Item 3, “Legal Proceedings” and Note 19, “Commitments and Contingencies,” to our consolidated financial statements.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
•Borrowings, financing costs and financial leverage. On May 30, 2024, the Company and SHH entered into Amendment No. 4 to the Senior Secured Credit Facilities, which provided for the issuance of term loans to the Company in an aggregate principal amount of $1,509.4 million maturing on May 30, 2031. On the same date, the Company issued Secured Notes in an aggregate principal amount of $750.0 million, which bear interest at an annual rate of 7.375% and mature on June 1, 2031. The proceeds from the Refinancing Term Loans and the issuance of the Secured Notes, along with cash on the balance sheet, were used to refinance all of the Company’s previously outstanding term loans due December 2026.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
Amortization of intangible assets primarily consists of expense associated with customer relationship intangible assets, the majority of which relate to the fair values attributed to these assets upon the recapitalization of the Company in connection with the acquisition by the Sponsors in 2015. These customer relationship intangible assets were initially assigned a weighted average useful life of ten years and have a remaining useful life of approximately one year. These customer relationship intangible assets accounted for approximately $48.4 million of our current annual amortization expense and are expected to be fully amortized in 2025. Amortization expense fluctuates when we have an acquisition, disposition, impairment charge, or as their useful lives expire.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
During the year ended December 31, 2022, we recorded an impairment charge of $9.6 million related to a joint venture investment, which was acquired as part of the 2020 acquisition of Iotron Industries Canada, Inc.. Due to a shift in business strategy, the joint venture did not proceed. Based on these facts and circumstances, we concluded that the investment was impaired as of June 30, 2022.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
(thousands of U.S. dollars) 2024 2023 $ Change % Change Operating expenses for the year ended December 31, Selling, general and administrative expenses $242,630 $236,667 $5,963 2.5% Amortization of intangible assets 62,039 63,799 (1,760) (2.8)% Total operating expenses $304,669 $300,466 $4,203 1.4%
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
(d)Represents (i) certain costs related to acquisitions and the integration of recent acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018, (iv) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (v) professional fees, payroll costs, and other costs, including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility. The year ended December 31, 2023 includes a $1.0 million cancellation fee received from a tenant in connection with the termination of an office space lease at the Nordion facility.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
(j)Interest expense, net presented in this reconciliation for the year ended December 31, 2023 has been adjusted to conform to the current year presentation to include interest expense, net on Term Loan B due 2026 attributable to the loan proceeds that were used to fund the $408.0 million Illinois EO litigation settlement.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
As described in more detail below, on March 1, 2024, the Company and SHH entered into Amendment No. 3 to the Revolving Credit Facility. Amendment No. 3 did not materially change the terms and conditions of the Credit Agreement, including
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedMD&A
Year Ended December 31, (in thousands) 2025 2024 2023 Net income $ 77,949 $ 44,398 $ 51,376 Amortization of intangible assets 41,798 79,377 81,348 Share-based compensation(a) 31,068 36,896 32,364 Loss on refinancing of debt(b) 1,462 24,168 — Loss (gain) on foreign currency and derivatives not designated as hedging instruments, net(c) 58 2,448 (1,552) Business optimization expenses(d) 7,504 7,662 8,068 9,368 Professional services relating to EO sterilization facilities(e) 46,225 32,694 45,312 Georgia Illinois EO litigation settlement(f) — 35,000 Secondary offering and other shareholder activities(g) 1,864 settlements(f) 64,943 — Accretion of asset retirement obligations(h) obligations(g) 2,321 2,638 2,413 Income tax benefit associated with pre-tax adjustments(i) adjustments(h) (28,478) (33,487) (49,597) Adjusted Net Income 245,414 198,500 204,326 Interest expense, net(j) net 155,722 164,691 142,878 Depreciation(k) Depreciation(i) 94,630 82,420 76,577 Income tax provision applicable to Adjusted Net Income(l) Income(j) 98,035 102,963 104,248 Adjusted EBITDA(m) EBITDA(k) $ 593,801 $ 548,574 $ 528,029
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Among other changes, Amendment No. 3 5 provides (i) for new an increase in the commitments under the existing Revolving Credit Facility to replace the existing revolving commitments in an aggregate principal amount of $83.0 million, Facility, (ii) that certain of the lenders providing revolving credit commitments shall also provide additional commitments for the issuance of letters of credit under the Revolving Credit Facility in an aggregate principal amount of $37.5 million and (iii) for the extension of extends the maturity date of the Revolving Credit Facility to March 1, 2029. April 30, 2030.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The decrease increase in cash and cash equivalents was attributable to $179.0 million of purchases of property, plant and equipment, $50.6 $287.2 million of cash used in financing provided by operating activities and a $17.4 $16.1 million decline increase due to favorable changes in foreign currency exchange rates, partially offset by $224.2 $138.0 million of purchases of property, plant and equipment and $100.5 million of cash provided by operating used in financing activities.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Among other changes, Amendment No. 4 6 provides for Refinancing the refinancing lenders to provide term loans (the “Repriced Term Loans Loans”) to SHH in an aggregate principal amount of $1,509.4 million. $1,419.5 million, which reflects the balance after the Company’s application of $75.0 million of available cash to repay outstanding borrowings under its term loan facility.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase in net cash provided by operating activities in 2024 the year ended December 31, 2025 compared to the prior year was due mainly to the timing of a $43.2 million increase in gross profit, a $15.9 million decrease in cash outflows paid for the Illinois interest and Georgia EO litigation settlements. a $5.0 million decrease in cash paid for income taxes.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Provision for income taxes for the year ended December 31, 2024 2025 differed from the statutory rate of 21% primarily due to a net increase recognition of the cumulative tax effects of the change in U.S. income tax laws under the OBBBA associated with the accounting for the valuation allowance attributable to the limitation on the deductibility of interest expense and the foreign rate expense.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Product revenues increased $14.9 $9.2 million, or 10.4%, 5.8%, to $167.9 million in the year ended December 31, 2025 as compared to $158.6 million in the year ended December 31, 2024 as compared to $143.7 million in the year ended December 31, 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The This refinancing activity primarily resulted in the write off of certain unamortized debt issuance costs and discounts on the Term Loans due 2026. 2026 and the expensing of certain new debt issuance costs and discounts upon the issuance of the Refinancing Term Loans (as defined below) and Secured Notes.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
For In addition, for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, we recorded costs of $46.2 million, $32.7 million, $45.3 million and $72.6 $45.3 million, respectively, representing of litigation and other professional fees and other expenses related to litigation associated with our EO sterilization facilities.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Other income, net primarily consists of changes in the fair value of the embedded derivatives in Nordion’s contracts, contracts and the net impact of pension related benefits and the income related to deferred income on a lease associated with the 2018 divestiture of the Medical Isotopes business. pension-related benefits.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Among other changes, Amendment No. 3 5 provides (i) for new an increase in the commitments under the existing Revolving Credit Facility to replace the existing revolving commitments in an aggregate principal amount of $83.0 million, $176.2 million (ii) that certain of the lenders providing revolving credit commitments shall also provide additional commitments for the issuance of letters of credit under the Revolving Credit Facility in an aggregate principal amount of $37.5 $186.3 million and (iii) for the extension of the maturity date of the Revolving Credit Facility to March 1, 2029. April 30, 2030.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Adjusted Net Income was $245.4 million for the year ended December 31, 2025, as compared to $198.5 million for the year ended December 31, 2024, as compared to $204.3 million for the year ended December 31, 2023, primarily due to the factors described above.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesMD&A
Costs associated with support functions that are not directly associated with one of the three reportable segments, such as corporate operating expenses for executive management, accounting, information technology, legal, human resources, treasury, investor relations, corporate development, tax, purchasing, and marketing, are allocated to the segments primarily based on net revenue.
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SHC/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.